Moreover, using Linsitinib in combination with a MEK inhibitor to treat colorectal cancer cells with active MAPK demonstrated synergistic antitumor effects on the Linsitinib‐resistant cell lines 27. This evidence concerns the gene MAP2K7 and colorectal cancer.